Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

r at 5:45 pm CT on Monday, December 9, in the La Nouvelle Ballroom C.

The following posters will be presented by the investigators from The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital:

Activities Of Commonly Used Tyrosine Kinase Inhibitors Against Wild Type c-KIT And Potential Impact On Normal Hematopoiesis.  Session Name: Molecular Pharmacology, Drug Resistance: Poster III.  Presentation on Monday, December 9, 2013 from 6:00 - 8:00 pm in Hall E.

The Combination Of FLT3 Inhibition And Hypomethylation Confers Synergistic Antileukemic Effects On FLT3-ITD Positive AML Cell Lines And Primary Cells: Session Name: Acute Myeloid Leukemia: Therapy, excluding Transplantation: Poster III.  Presentation on Monday, December 9, 2013 from 6:00 - 8:00 pm in Hall E.

The abstracts and posters can be accessed on the ASH website at http://hematology.org.

Third Quarter Results
Revenues were $7.7 million and $4.3 million for the quarters ended September 30, 2013 and 2012, respectively.  The increase of $3.4 million was primarily due to acceleration in the recognition of license fee revenue related to the Company's collaboration with Astellas Pharma.  In March 2013, the Company received a notice of termination of the agreement from Astellas, which termination was effective September 2013. 

Research and development expenses were $4.5 million and $8.2 million for the quarters ended September 30, 2013 and 2012, respectively.  The decrease of $3.7 million was primarily due to lower quizartinib research and development expenses.  This resulted from a reduction in the number of patients being treated and followed in our Phase 2 clinical trial, in which enrollment was completed in late 2011. 

General and administrative expenses were
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... and SHENZHEN, China , July 31, ... the purchase of an Irys™System by ... BioNano,s platform to enable comprehensive exploration of human structural ... various organisms of interest, including those where no reference ... to develop new methods for multiplexing on the Irys ...
(Date:7/31/2014)... Chicago, IL (PRWEB) July 31, 2014 ... wave of automation across the U.S., increasing unemployment, ... middle class. It is a Catch 22—we ... internationally, but this means fewer jobs,” says economist ... the just-released Pollina Corporate Top 10 Pro-Business States ...
(Date:7/31/2014)... 2014 Sales Horizons, a leader in ... sales training course – Mastering the Complex Sale ... , Drawn from proven sales training programs used by ... Complex Sale online sales training course is available to ... face-to-face contact with customers, like technical support, engineers, clinical ...
(Date:7/30/2014)... 2014 A study presented at the ... efficacy of CSL Behring,s C1 Inhibitor (C1-INH) concentrate ... highly sensitized patients. C1-INH is a human protein ... The study shows that post-transplant treatment ... levels of complement components 3 and 4, suggesting ...
Breaking Biology Technology:BioNano Genomics Announces the Purchase of the Irys System by BGI 2BioNano Genomics Announces the Purchase of the Irys System by BGI 3BioNano Genomics Announces the Purchase of the Irys System by BGI 4ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 2ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 3ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 4Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 3Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3
... Jan. 14 Sigma-Aldrich Corporation,(Nasdaq: SIAL ), will ... Wednesday, February 11, 2009, at 11:00 a.m. Eastern Time,(10 a.m. ... being webcast by Thomson/CCBN and can be accessed at,Sigma-Aldrich,s Web ... The webcast is also being distributed through the Thomson ...
... Jan. 14 /PRNewswire-FirstCall/ - BioSyntech, Inc. (TSX: BSY), ... medicine, today announced that it will conclude enrolment ... its cartilage repair device, BST-CarGel(R). To date, the ... participating clinical sites will be permitted to enrol ...
... SAN FRANCISCO, Jan. 14 Inverseon, Inc. ( http://www.inverseon.com ... from the United States Patent Office covering its oral ... clinical asthma study was published in the January 10, ... would be the first patent for the utilization of ...
Cached Biology Technology:Sigma-Aldrich Corporation's 4th Quarter 2008 Earnings Conference Call 2BioSyntech to conclude enrolment for pivotal BST-CarGel(R) trial in February 2009 2BioSyntech to conclude enrolment for pivotal BST-CarGel(R) trial in February 2009 3BioSyntech to conclude enrolment for pivotal BST-CarGel(R) trial in February 2009 4Inverseon's Asthma Therapy Receives Notice of Allowance; Clinical Trial Highlighted in Lancet 2
(Date:7/31/2014)... SHELTON, Conn. , July 31, 2014 /PRNewswire/ ... on the growing m-commerce market, reminds investors and ... generation smart wallet, Wocket™, that it will be on-air ... biometrically secure Wocket smart wallet will be featured ... consumer oriented television show that airs on the ...
(Date:7/31/2014)... new meta-analyses involving tree nuts (almonds, Brazil nuts, cashews, ... recently published in the online publications, British Medical ... ONE (ii). The BMJ Open article ... syndrome (MetS) criteria and showed that tree nut consumption ... blood glucose. The PLOS ONE article focused ...
(Date:7/30/2014)... reversible epigenetic processes to regulate its genes, and adapt ... picture of the genome regulation taking place in the ... Genome Biology and illustrates how the truffle deals ... The authors say this may shed light on how ... truffles (Tuber melanosporum), also known as Prigord truffles, have ...
Breaking Biology News(10 mins):NXT-ID's Next Generation Biometric Smart Wallet Featured on NewsWatch Consumer Show on the History Channel and FYI Network Today, July 31st 2NXT-ID's Next Generation Biometric Smart Wallet Featured on NewsWatch Consumer Show on the History Channel and FYI Network Today, July 31st 3New international tree nut council study looks at nuts, diabetes and metabolic syndrome 2How black truffles deal with the jumpers in their genome 2
... 2010 The television news and entertainment media are ... and helpful information about health and weight to Americans, ... Pace University in New York City. The National ... Prevent (STOP) Obesity Alliance organized the program, called "Weighty ...
... 2010) The goal of tissue engineering is to ... then transplant them into patients, where they are fully integrated. ... high-throughput imaging systems that allow researchers to directly monitor transplanted ... the culturing and implantation techniques, as well as the design ...
... Los Angeles, CA (1 April 2010)Two conservationists who have ... from the brink of extinction and ensure their habitat ... Tyler Prize for Environmental Achievement, one of the world,s ... inception in 1973, the Tyler Prize continues to be ...
Cached Biology News:Eating disorders, obesity and communications experts tackle 'weighty matters' 2Tissue engineering, imaging neuronal circuits featured in Cold Spring Harbor Protocols 2Leading conservation scientists awarded prestigious 2010 Tyler Environmental Prize 2Leading conservation scientists awarded prestigious 2010 Tyler Environmental Prize 3
...
Multidrop DW is a high-speed automated dispenser for Deep Well plates, 1.1 ml test tubes and 96-well plates. Designed for accuracy and precision, the Multidrop DW dispenses up to eight different reag...
... Rotor for use in the ... and Centra-MP4/MP4R. Perfect for ... and other difficult to separate ... containment. Complete with rotor and ...
... 45° Fixed Angle rotor for ... CL2, Centra CL3/CL3R, HN-SII or ... style rotor accepts 15 mL ... disposable conical tubes as well ...
Biology Products: